Phase II Selection

Authored by: P.Y. Liu , James Moon , Michael LeBlanc

Handbook of Statistics in Clinical Oncology

Print publication date:  March  2012
Online publication date:  March  2012

Print ISBN: 9781439862001
eBook ISBN: 9781439862018
Adobe ISBN:


 Download Chapter



When there are multiple promising new therapies in a disease setting, it may not be feasible to test all of them against the standard treatment in a definitive phase III trial. The sample sizes required for a phase III study with more than three arms could be prohibitive [1]. In addition, the analysis can be highly complex and prone to errors due to the large number of possible comparisons in a multi-arm study. An alternative strategy is to screen the new therapies first in a phase II setting and choose one to test against a standard treatment in a simple two-arm phase III trial. Selection designs can be used in such circumstances.

Search for more...
Back to top

Use of cookies on this website

We are using cookies to provide statistics that help us give you the best experience of our site. You can find out more in our Privacy Policy. By continuing to use the site you are agreeing to our use of cookies.